# DESCRIPTION

## STATEMENT OF FEDERALLY FUNDED RESEARCH

- acknowledge government funding

## TECHNICAL FIELD OF THE INVENTION

- define technical field

## BACKGROUND OF THE INVENTION

- describe SARS-CoV-2 and COVID-19

## SUMMARY OF THE INVENTION

- introduce method for treating SARS-CoV-2
- describe inhibitor of SARS-CoV-2 binding to L-SIGN

## DETAILED DESCRIPTION OF THE INVENTION

- define terms
- describe therapeutically effective amount
- explain subject and pharmaceutically acceptable
- introduce effective dose
- describe practice of the invention
- motivate SARS-CoV-2 receptor on endothelial cells
- list reagents and antibodies
- describe SARS-CoV-2 pseudovirus production and infection inhibition assay
- outline flow cytometric analysis
- summarize western blotting and lectin blotting
- describe histology and microscopy
- outline glycan structural analysis
- introduce L-SIGN as a novel SARS-CoV-2 receptor
- describe L-SIGN's binding to high-mannose N-glycans on spike protein
- summarize L-SIGN's expression on liver sinusoidal endothelial cells (LSECs) and lymph node lymphatic endothelial cells (LECs)
- describe blocking L-SIGN function to reduce CoV2-type infection
- discuss L-SIGN's role in coagulopathy and thrombosis in severe COVID-19 patients
- compare L-SIGN to ACE2 as an entry receptor for SARS-CoV-2
- describe the molecular basis of L-SIGN recognition of spike protein
- discuss the implications of L-SIGN-mediated SARS-CoV-2 infection on endothelial cell activation and coagulopathy
- summarize the results and their significance in understanding COVID-19 pathogenesis
- provide a conclusion and potential therapeutic options

